Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026)

Acadia Pharmaceuticals' Receivables history runs 11 years deep, the most recent figure standing at $148.4 million for Q1 2026.

• On a quarterly basis, Receivables rose 30.49% year-over-year to $148.4 million in Q1 2026; TTM through Mar 2026 was $148.4 million, a 30.49% increase from a year earlier, with the FY2025 full-year figure at $148.2 million, up 41.58% from the prior year.
• Receivables steadied at $148.4 million in Q1 2026 per ACAD's latest filing, from $148.2 million in the prior quarter.
• Across five years, Receivables topped out at $148.4 million in Q1 2026 and bottomed at $56.1 million in Q3 2022.
• The 5-year median for Receivables is $102.4 million (2023), against an average of $99.9 million.
• Across the five-year window, Receivables slipped 8.97% in 2022 and surged 68.4% in 2023, its largest moves.
• Year by year, Receivables stood at $63.1 million in 2022, then jumped by 62.25% to $102.4 million in 2023, then increased by 2.29% to $104.7 million in 2024, then surged by 41.58% to $148.2 million in 2025, then advanced by 0.1% to $148.4 million in 2026.
• Per Business Quant, the three latest ACAD Receivables figures stand at $148.4 million (Q1 2026), $148.2 million (Q4 2025), and $139.4 million (Q3 2025).